Literature DB >> 3495666

The toxicity of recombinant human interleukin-2 in rats following intravenous infusion.

Y L Matory, A E Chang, E H Lipford, R Braziel, C L Hyatt, S A Rosenberg.   

Abstract

Studies of recombinant interleukin-2 (RIL-2) administered by continuous intravenous infusion revealed hepatocellular toxicity and redistribution of lymphoid cells. This finding was different from the normal findings seen in rats receiving comparable infusions of the vehicle.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3495666      PMCID： PMC2625483     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN： 0027-9684            Impact factor:   1.798


  20 in total

1.  In vivo administration of Interleukin-2 enhances specific alloimmune responses.

Authors:  S A Rosenberg; P J Spiess; S Schwarz
Journal:  Transplantation       Date:  1983-06       Impact factor: 4.939

2.  Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

Authors:  M A Cheever; P D Greenberg; A Fefer; S Gillis
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

3.  Adoptive immunotherapy of cancer: accomplishments and prospects.

Authors:  S A Rosenberg
Journal:  Cancer Treat Rep       Date:  1984-01

4.  The fate of interleukin-2 after in vivo administration.

Authors:  J H Donohue; S A Rosenberg
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

5.  In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells.

Authors:  S H Hefeneider; P J Conlon; C S Henney; S Gillis
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

6.  Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.

Authors:  J U Gutterman; S Fine; J Quesada; S J Horning; J F Levine; R Alexanian; L Bernhardt; M Kramer; H Spiegel; W Colburn; P Trown; T Merigan; Z Dziewanowski
Journal:  Ann Intern Med       Date:  1982-05       Impact factor: 25.391

7.  T cell factor (interleukin 2) allows in vivo induction of T helper cells against heterologous erythrocytes in athymic (nu/nu) mice.

Authors:  H Stötter; E Rüde; H Wagner
Journal:  Eur J Immunol       Date:  1980-09       Impact factor: 5.532

Review 8.  Interferons: rationale for clinical trials in neoplastic disease.

Authors:  E C Borden
Journal:  Ann Intern Med       Date:  1979-09       Impact factor: 25.391

9.  Long-term vascular access in the rat: importance of asepsis.

Authors:  M B Popp; M F Brennan
Journal:  Am J Physiol       Date:  1981-10

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.